KeyBanc Reaffirms Their Buy Rating on Medidata Solutions

By Jason Carr

KeyBanc analyst Brent Bracelin reiterated a Buy rating on Medidata Solutions (NASDAQ: MDSO) today and set a price target of $86. The company’s shares closed on Friday at $75.86.

According to, Bracelin is a 5-star analyst with an average return of 12.0% and a 72.8% success rate. Bracelin covers the Technology sector, focusing on stocks such as Cornerstone Ondemand, Riverbed Technology, and Tyler Technologies.

Medidata Solutions has an analyst consensus of Strong Buy, with a price target consensus of $86.29.

The company has a one year high of $85.92 and a one year low of $46.10. Currently, Medidata Solutions has an average volume of 646.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Medidata Solutions, Inc. provides cloud based solutions for life sciences that enhance the efficiency of customer’s clinical development processes from concept to conclusion, optimizing their research and development investments. It provides technology solutions and data analytics aimed at enabling effective and safe development, using secure cloud and hybrid cloud infrastructure to instantly connect users over the Internet. The company customers include pharmaceutical, biotechnology, and medical device companies, academic institutions, contract research organizations and other organizations engaged in clinical trials. The company was founded by Glen M. de Vries, Edward F. Ikeguchi and Tarek A. Sherif in June 1999 and is headquartered in New York, NY.